Plain-English translation of NCT06157502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a neuroprotective medication, can improve recovery when given together with standard intravenous thrombolysis (a clot-busting drug) to patients having an acute ischemic stroke. Standard thrombolysis alone helps many stroke patients, but more than half still experience lasting disability. This medication is designed to protect brain cells from additional damage during and after a stroke, potentially working alongside the clot-busting therapy to improve outcomes.
Current stroke treatment uses clot-busting drugs, which are effective but don't prevent all brain cell damage. This medication is designed to reduce the cascade of damage that happens to brain tissue after a stroke, and researchers want to see if adding it to standard treatment can help more patients recover better function.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the study medication or a placebo, both given intravenously alongside your standard stroke thrombolysis treatment. You will receive injections for 10–14 days. The research team will check on your health and recovery at specific intervals, with the main evaluation happening 90 days after your stroke to measure how well you are functioning and to monitor for any side effects.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
China